Endonovo Therapeutics (ENDV) Other Working Capital Changes (2016 - 2023)
Endonovo Therapeutics has reported Other Working Capital Changes over the past 9 years, most recently at $2922.0 for Q3 2023.
- Quarterly results put Other Working Capital Changes at $2922.0 for Q3 2023, up 158.44% from a year ago — trailing twelve months through Sep 2023 was $6673.0 (up 113.42% YoY), and the annual figure for FY2022 was $7750.0, up 132.49%.
- Other Working Capital Changes for Q3 2023 was $2922.0 at Endonovo Therapeutics, up from -$2533.0 in the prior quarter.
- Over the last five years, Other Working Capital Changes for ENDV hit a ceiling of $29225.0 in Q4 2020 and a floor of -$41750.0 in Q4 2021.
- Median Other Working Capital Changes over the past 5 years was -$2533.0 (2023), compared with a mean of -$1368.9.
- Biggest five-year swings in Other Working Capital Changes: skyrocketed 3915.79% in 2021 and later tumbled 306.82% in 2022.
- Endonovo Therapeutics' Other Working Capital Changes stood at -$1655.0 in 2019, then soared by 1865.86% to $29225.0 in 2020, then plummeted by 242.86% to -$41750.0 in 2021, then soared by 137.66% to $15725.0 in 2022, then tumbled by 81.42% to $2922.0 in 2023.
- The last three reported values for Other Working Capital Changes were $2922.0 (Q3 2023), -$2533.0 (Q2 2023), and -$9441.0 (Q1 2023) per Business Quant data.